Publications associées à Erythropoiesis-stimulating agent

Multi-modal assessment of long-term erythropoietin treatment after neonatal hypoxic-ischemic injury in rat brain

Erythropoietin (EPO) has been recognized as a neuroprotective agent. In animal models of neonatal brain injury, exogenous EPO has been shown to reduce lesion size, improve structure and function. Experimental studies have focused on short course treatment ...

Public Library of Science2014

A KRAB/KAP1-miRNA Cascade Regulates Erythropoiesis Through Stage-Specific Control of Mitophagy

Didier Trono, Jiri Vanicek, Sandra Eloise Kjeldsen, Isabelle Barde, Sonia Verp, Adamantia Kapopoulou, Andrea Corsinotti, Benjamin Rauwel, Ray Marcel Marin Florez

During hematopoiesis, lineage- and stage-specific transcription factors work in concert with chromatin modifiers to direct the differentiation of all blood cells. Here, we explored the role of KRAB-containing zinc finger proteins (KRAB-ZFPs) and their cofa ...

American Association for the Advancement of Science2013

Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia

Patrick Aebischer, Nicole Déglon, Bernard Schneider

BACKGROUND: Existing animal models of anemia inadequately reflect the hematocrit usually present in chronic renal failure (CRF) patients and do not permit long-term treatment studies. The transgenic mouse strain 134.3LC (Epo-TAg(H)) displays a severe chron ...

2002

Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts

Patrick Aebischer, Nicole Déglon, Bernard Schneider

The transplantation of polymer encapsulated myoblasts genetically engineered to secrete erythropoietin (Epo) may obviate the need for repeated parenteral administration of recombinant Epo as a treatment for chronic renal failure, cancer or AIDS-associated ...

1998